Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Novel compounds active on staphylococci].

B Fantin1

  • 1Service de médecine interne, hôpital Beaujon, 100, boulevard du Général Leclerc, 92118 Clichy, France. bruno.fantin@bjn.ap-hop-paris.fr

Annales Francaises D'Anesthesie Et De Reanimation
|June 25, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temocillin efficacy and emergence of resistance in Enterobacter cloacae Complex in a murine peritonitis model.

The Journal of antimicrobial chemotherapy·2026
Same author

Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infections.

International journal of antimicrobial agents·2023
Same author

Evolution of fluoroquinolone-resistant Escherichia coli in the gut after ciprofloxacin treatment.

International journal of medical microbiology : IJMM·2022
Same author

[Characteristics of patients admitted from emergency units in 18 internal medicine departments and organisation of these departments: A cross sectional study from SNFMI (SiFMI study group) in 2015].

La Revue de medecine interne·2020
Same author

Dimercaptosuccinic acid in combination with carbapenems against isogenic strains of Escherichia coli producing or not producing a metallo-β-lactamase in vitro and in murine peritonitis.

The Journal of antimicrobial chemotherapy·2020
Same author

Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2020
Same journal

Annales francaises d'anesthesie et de reanimation·2020
Same journal

[Multimodal approach to enhance filter lifespan: are all actions equal?].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Disparity of French Emergency medical services equipment: disparity of funding allocation or of management quality?].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Eligibility to a Maastricht III - type organ donation according to the protocol proposed by the French organ procurement organization (Agence de la biomedicine) among patients in a medico surgical intensive care unit].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Enhanced recovery after elective colorectal surgery: reply].

Annales francaises d'anesthesie et de reanimation·2014
Same journal

[Aorto-right atrial fistula as complication of aortic dissection].

Annales francaises d'anesthesie et de reanimation·2014
See all related articles

New research explores novel anti-staphylococcal compounds due to high rates of methicillin-resistant staphylococci. Current treatments like glycopeptides have limitations, prompting the investigation of agents such as quinupristine-dalfopristine and linezolide.

Area of Science:

  • Microbiology and Infectious Diseases
  • Pharmacology and Therapeutics

Context:

  • High prevalence of methicillin-resistant staphylococci (MRSA) in healthcare settings.
  • Limitations of current glycopeptide antibiotics, including suboptimal pharmacokinetics, pharmacodynamics, and emerging resistance.
  • Need for effective alternatives to combat staphylococcal infections.

Purpose:

  • To review and assess the potential of novel anti-staphylococcal agents.
  • To evaluate quinupristine-dalfopristine (Synercid) and linezolide as therapeutic options.

Summary:

  • Discusses the critical need for new antibiotics against staphylococci due to persistent MRSA infections.
  • Highlights the inadequacy of glycopeptides, citing poor drug properties and reduced bacterial sensitivity.
  • Examines the therapeutic promise of quinupristine-dalfopristine and linezolide.

Related Experiment Videos

Impact:

  • Informs clinicians and researchers about emerging anti-staphylococcal therapies.
  • Supports the development of new treatment strategies for resistant bacterial infections.
  • Addresses the urgent global health challenge posed by antibiotic resistance.